Antibody-Producing Cell Stability via BCL6 and Blimp-1 Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for culturing human monoclonal antibody-producing B cells are unstable and have limited replicative life span, making it difficult to maintain long-term antibody production.
Innovation Solution
Regulating the expression of BCL6 and Blimp-1 in antibody-producing cells to stabilize them in a plasmablast-like stage, allowing for prolonged replicative life span and sustained antibody production by co-expressing both proteins and using compounds like STAT5 and IL-21 to influence their expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If human B cells are cultured ex vivo to produce monoclonal antibodies, then antibody production capability is achieved, but the cells undergo senescence and have limited replicative life span
Solution Approach 1:
The patent changes the molecular parameters of the B cells by introducing exogenous genes (c-MYC, BCL6, and/or BLIMP1) to alter their biological behavior. This transforms the cells from a finite, senescent state to an immortalized state capable of indefinite proliferation while maintaining antibody production, directly resolving the contradiction between productivity and duration
Solution Approach 2:
The patent uses viral vectors as intermediaries to deliver the immortalizing genes into B cells. These vectors act as mediators that enable stable genetic modification without directly causing the immortalization effect, allowing the cells to acquire extended life span while maintaining their antibody-producing function
2Duration of action of stationary object
If B cells are fused with cancer cells to create hybridoma cells, then indefinite proliferation is achieved, but the resulting hybridomas are unstable and difficult to maintain
Solution Approach 1:
The patent extracts only the necessary genetic elements for immortalization (c-MYC, BCL6, BLIMP1 genes) from cancer cells, rather than performing complete cell fusion. This selective extraction provides the proliferation capability of cancer cells while avoiding their instability and other unwanted characteristics, thereby improving culture reliability
Solution Approach 2:
The patent applies local quality modification by introducing specific genes at controlled levels into B cells. Rather than global transformation through cell fusion, the selective expression of immortalizing genes in specific B cell populations creates stable, homogeneous cultures with consistent antibody production characteristics
Data Source
AI summary
The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.